Nexavar — Medica
Acute myeloid leukemia
Initial criteria
- age ≥ 18 years
- FLT3-ITD mutation-positive disease as detected by an approved test
- EITHER used in combination with azacitidine or decitabine OR patient has had an allogeneic stem cell transplant and is in remission
Approval duration
1 year